AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Alternatively, BCR-ABL fused protein, characteristic of CML, activates Akt and ERK pathways, which leads to deregulated growth and resistance to apoptosis (Hazlehurst et al., 2009; Quintas-Cardama and Cortes, 2009).